

# Jack Hirsh

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/10785688/jack-hirsh-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

274  
papers

41,121  
citations

99  
h-index

201  
g-index

282  
ext. papers

45,009  
ext. citations

11.7  
avg, IF

6.98  
L-index

#	Paper	IF	Citations
274	Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1330-5	59.2	2297
273	Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 160S-198S	5.3	1648
272	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 83, 416-420	7	1098
271	Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. <i>Chest</i> , <b>2001</b> , 119, 64S-94S	5.3	1026
270	A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 677-81	59.2	983
269	Heparin. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 156S-74	59.2	909
268	Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. <i>Circulation</i> , <b>2002</b> , 105, 1650-5	16.7	907
267	A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. <i>New England Journal of Medicine</i> , <b>1999</b> , 340, 901-7	59.2	876
266	The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 204S-233S	5.3	852
265	Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. <i>Chest</i> , <b>2001</b> , 119, 8S-21S	5.3	770
264	Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 188S-203S	5.3	750
263	A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1133-8	59.2	677
262	Management of anticoagulation before and after elective surgery. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 1506-11	59.2	655
261	Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 1109-14	59.2	633
260	Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 844S-886S	5.3	603
259	Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2004</b> , 128, 211-9	1.5	576
258	Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. <i>New England Journal of Medicine</i> , <b>1979</b> , 301, 85S-8	59.2	562

257	Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 141S-159S	5.3	560
256	Accuracy of clinical assessment of deep-vein thrombosis. <i>Lancet, The</i> , <b>1995</b> , 345, 1326-30	4.0	556
255	A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. <i>New England Journal of Medicine</i> , <b>1972</b> , 287, 324-7	59.2	547
254	Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 234S-264S	5.3	494
253	Oral anticoagulant drugs. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 1865-75	59.2	481
252	A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 925-9	59.2	461
251	A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 524-9	59.2	454
250	Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 1260-4	59.2	454
249	Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. <i>Circulation</i> , <b>1996</b> , 93, 2212-45	16.7	439
248	Managing oral anticoagulant therapy. <i>Chest</i> , <b>2001</b> , 119, 22S-38S	5.3	436
247	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1704-14	59.2	428
246	American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. <i>Circulation</i> , <b>2003</b> , 107, 1692-711	16.7	427
245	Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. <i>Chest</i> , <b>1998</b> , 114, 489S-510S	5.3	423
244	Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. <i>New England Journal of Medicine</i> , <b>1982</b> , 306, 189-94	59.2	418
243	Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 627S-644S	5.3	398
242	Platelet-active drugs : the relationships among dose, effectiveness, and side effects. <i>Chest</i> , <b>2001</b> , 119, 39S-63S	5.3	380
241	Small subcutaneous doses of heparin in prevention of venous thrombosis. <i>New England Journal of Medicine</i> , <b>1973</b> , 288, 545-51	59.2	378
240	The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. <i>New England Journal of Medicine</i> , <b>1988</b> , 318, 404-7	59.2	370

239	Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. <i>Chest</i> , <b>1998</b> , 114, 445S-469S	5.3	358
238	Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. <i>Chest</i> , <b>1995</b> , 108, 258S-275S	5.3	353
237	Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 199S-233S	5.3	350
236	Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. <i>Circulation</i> , <b>2001</b> , 103, 2994-3018	16.7	342
235	Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1439-44	59.2	336
234	Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. <i>American Journal of Medicine</i> , <b>1996</b> , 100, 269-77	2.4	322
233	Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. <i>New England Journal of Medicine</i> , <b>1989</b> , 320, 352-7	59.2	302
232	Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. <i>Chest</i> , <b>1985</b> , 88, 819-28	5.3	290
231	Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>1995</b> , 74, 606-611	7	284
230	American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. <i>Journal of the American College of Cardiology</i> , <b>2003</b> , 41, 1633-52	15.1	264
229	Use of antithrombotic agents during pregnancy. <i>Chest</i> , <b>2001</b> , 119, 122S-131S	5.3	263
228	Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e89S-e119S	5.3	262
227	A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. <i>Chest</i> , <b>1990</b> , 98, 1473-9	5.3	258
226	Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. <i>European Heart Journal</i> , <b>2004</b> , 25, 166-81	9.5	245
225	Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 71S-109S	5.3	240
224	Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participantsRdata from seven trials. <i>BMJ, The</i> , <b>2011</b> , 342, d3036	5.9	234
223	An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. <i>Archives of Internal Medicine</i> , <b>2003</b> , 163, 2518-24		232
222	Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. <i>Chest</i> , <b>1995</b> , 108, 231S-246S	5.3	228

221	Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. <i>Lancet, The</i> , <b>1988</b> , 1, 1242-5	40	226
220	Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 110S-112S	5.3	220
219	Characterization of the stress-inducing effects of homocysteine. <i>Biochemical Journal</i> , <b>1998</b> , 332 ( Pt 1), 213-21	3.8	203
218	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1937-1945	59.2	202
217	Prevention and treatment of postphlebotic syndrome: results of a 3-part study. <i>Archives of Internal Medicine</i> , <b>2001</b> , 161, 2105-9		187
216	New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , <b>2008</b> , 133, 234S-256S	5.3	186
215	The vexing problem of guidelines and conflict of interest: a potential solution. <i>Annals of Internal Medicine</i> , <b>2010</b> , 152, 738-41	8	184
214	A Comparison of the Safety and Efficacy of Oral Anticoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 84, 805-810	7	181
213	Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. <i>Circulation</i> , <b>1996</b> , 93, 870-8	16.7	179
212	Beyond unfractionated heparin and warfarin: current and future advances. <i>Circulation</i> , <b>2007</b> , 116, 552-60	16.7	178
211	Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, 53S-70S	5.3	177
210	American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?. <i>Chest</i> , <b>2009</b> , 135, 513-520	5.3	172
209	Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. <i>Chest</i> , <b>1992</b> , 102, 337S-351S	5.3	168
208	Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 67, 639-643	7	167
207	Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 935-42	27.4	164
206	Combined use of leg scanning and impedance plethysmography in suspected venous thrombosis. An alternative to venography. <i>New England Journal of Medicine</i> , <b>1977</b> , 296, 1497-500	59.2	160
205	A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. <i>Circulation</i> , <b>1995</b> , 91, 2184-7	16.7	152
204	Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. <i>New England Journal of Medicine</i> , <b>1981</b> , 304, 1561-7	59.2	151

203	Treatment of heparin-induced thrombocytopenia: a critical review. <i>Archives of Internal Medicine</i> , <b>2004</b> , 164, 361-9		147
202	A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. <i>Blood</i> , <b>1997</b> , 89, 3236-3242	2.2	146
201	Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. <i>Lancet, The</i> , <b>1987</b> , 1, 523-6	40	146
200	Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. <i>Lancet, The</i> , <b>2000</b> , 356, 1551-3	40	144
199	A randomized trial comparing 5-mg and 10-mg warfarin loading doses. <i>Archives of Internal Medicine</i> , <b>1999</b> , 159, 46-8		143
198	Risks to the Fetus of Anticoagulant Therapy During Pregnancy. <i>Thrombosis and Haemostasis</i> , <b>1989</b> , 61, 197-203	7	142
197	Platelet-active drugs: the relationships among dose, effectiveness, and side effects. <i>Chest</i> , <b>1998</b> , 114, 470S-488S	5.3	139
196	New anticoagulants. <i>Blood</i> , <b>2005</b> , 105, 453-63	2.2	136
195	Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. <i>Archives of Internal Medicine</i> , <b>1998</b> , 158, 2001-3		136
194	Hemorrhagic complications of anticoagulant treatment. <i>Chest</i> , <b>1995</b> , 108, 276S-290S	5.3	135
193	Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , <b>2012</b> , 141, e185S-e194S	5.3	131
192	Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. <i>Annals of Internal Medicine</i> , <b>2001</b> , 135, 108-11	8	128
191	How we diagnose and treat deep vein thrombosis. <i>Blood</i> , <b>2002</b> , 99, 3102-10	2.2	128
190	The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. <i>Chest</i> , <b>2001</b> , 119, 1S-2S	5.3	121
189	New anticoagulant drugs. <i>Chest</i> , <b>2001</b> , 119, 95S-107S	5.3	119
188	Elevated platelet-associated IgG in the thrombocytopenia of septicemia. <i>New England Journal of Medicine</i> , <b>1979</b> , 300, 760-4	59.2	118
187	Congenital antithrombin III deficiency. Incidence and clinical features. <i>American Journal of Medicine</i> , <b>1989</b> , 87, 34S-38S	2.4	114
186	Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. <i>Chest</i> , <b>2003</b> , 124, 349S-356S	5.3	113

185	Monitoring unfractionated heparin with the aPTT: Time for a fresh look. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 547-552	7	110
184	Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. <i>Circulation</i> , <b>1996</b> , 94, 1553-60	16.7	110
183	The International Normalized Ratio. <i>Archives of Internal Medicine</i> , <b>1994</b> , 154, 282		109
182	Effect of aspirin on mortality in the primary prevention of cardiovascular disease. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 621-9	2.4	108
181	Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. <i>Chest</i> , <b>2003</b> , 124, 379S-385S	5.3	108
180	New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , <b>2004</b> , 126, 265S-286S	5.3	108
179	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. <i>Thrombosis and Haemostasis</i> , <b>1994</b> , 71, 300-304	7	106
178	Hemorrhagic complications of anticoagulant treatment. <i>Chest</i> , <b>1992</b> , 102, 352S-363S	5.3	103
177	Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. <i>Archives of Internal Medicine</i> , <b>2000</b> , 160, 470-8		101
176	New antithrombotic agents. <i>Lancet, The</i> , <b>1999</b> , 353, 1431-6	40	100
175	Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 2605-9		96
174	Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. <i>Chest</i> , <b>2005</b> , 127, 1857-61	5.3	95
173	Use of antithrombotic agents during pregnancy. <i>Chest</i> , <b>1998</b> , 114, 524S-530S	5.3	90
172	A novel whole blood capillary technic for measuring the prothrombin time. <i>American Journal of Clinical Pathology</i> , <b>1987</b> , 88, 442-6	1.9	88
171	Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. <i>Circulation</i> , <b>2003</b> , 107, 2884-8	16.7	86
170	Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>1991</b> , 67, 3A-11A	3	86
169	A Comparison of General Anesthesia and Regional Anesthesia as a Risk Factor for Deep Vein Thrombosis Following Hip Surgery: A Critical Review. <i>Thrombosis and Haemostasis</i> , <b>1990</b> , 64, 497-500	7	86
168	The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. <i>Thrombosis and Haemostasis</i> , <b>1998</b> , 80, 413-417	7	85

167	Hemorrhagic complications of long-term anticoagulant therapy. <i>Chest</i> , <b>1989</b> , 95, 26S-36S	5.3	85
166	Current anticoagulant therapy--unmet clinical needs. <i>Thrombosis Research</i> , <b>2003</b> , 109 Suppl 1, S1-8	8.2	84
165	Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. <i>Journal of the American College of Cardiology</i> , <b>1998</b> , 31, 1493-8	15.1	82
164	Hemorrhagic complications of anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1986</b> , 12, 39-57	5.3	82
163	Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts). <i>New England Journal of Medicine</i> , <b>1975</b> , 293, 1174-8	59.2	77
162	Prevention of venous thrombosis by intermittent sequential calf compression in patients with intracranial disease. <i>Thrombosis Research</i> , <b>1979</b> , 15, 611-6	8.2	76
161	Low-molecular-weight heparin : A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. <i>Circulation</i> , <b>1998</b> , 98, 1575-82	16.7	73
160	Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. <i>Chest</i> , <b>1995</b> , 108, 247S-257S	5.3	73
159	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 566-574	16.2	72
158	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2008</b> , 5, 766-80		72
157	Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 625-630	7	71
156	Clinical features and diagnosis of venous thrombosis. <i>Journal of the American College of Cardiology</i> , <b>1986</b> , 8, 114B-127B	15.1	69
155	Use of antithrombotic agents during pregnancy. <i>Chest</i> , <b>1995</b> , 108, 305S-311S	5.3	67
154	Hemorrhagic complications of long-term anticoagulant therapy. <i>Chest</i> , <b>1986</b> , 89, 16S-25S	5.3	67
153	Clinical experts or methodologists to write clinical guidelines?. <i>Lancet, The</i> , <b>2009</b> , 374, 273-5	40	64
152	Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 85, 390-394	7	63
151	Induction of the acute-phase reaction increases heparin-binding proteins in plasma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 1568-74	9.4	63
150	The optimal duration of anticoagulant therapy for venous thrombosis. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1710-1	59.2	61



149	In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. <i>Thrombosis Research</i> , <b>2002</b> , 107, 241-4	8.2	60
148	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. <i>Blood</i> , <b>1999</b> , 93, 1231-1236	2.2	60
147	Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. <i>Archives of Internal Medicine</i> , <b>1999</b> , 159, 2029-32		60
146	"Therapeutic range" for oral anticoagulant therapy. <i>Chest</i> , <b>1986</b> , 89, 11S-15S	5.3	60
145	Epidemiology and pathogenesis of venous thrombosis. <i>Journal of the American College of Cardiology</i> , <b>1986</b> , 8, 104B-113B	15.1	59
144	The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. <i>Thrombosis Research</i> , <b>1985</b> , 40, 769-77	8.2	56
143	Anticoagulants during pregnancy. <i>Annual Review of Medicine</i> , <b>1989</b> , 40, 79-86	17.4	54
142	The Diagnosis of Clinically Suspected Venous Thrombosis. <i>Clinics in Chest Medicine</i> , <b>1984</b> , 5, 439-456	5.3	54
141	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 295-301	5.1	53
140	Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. <i>Archives of Internal Medicine</i> , <b>2001</b> , 161, 385-91		51
139	Translational success stories: development of direct thrombin inhibitors. <i>Circulation Research</i> , <b>2012</b> , 111, 920-9	15.7	50
138	Bleeding and management of bleeding. <i>Country Review Ukraine</i> , <b>2006</b> , 8, G38-G45		50
137	An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 69, 231-235	7	50
136	Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. <i>Chest</i> , <b>1995</b> , 108, 291S-301S	5.3	48
135	The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. An international multicenter study. <i>American Journal of Clinical Pathology</i> , <b>1995</b> , 103, 358-65	1.9	48
134	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , <b>2012</b> , 52, 1203-12	2.9	47
133	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 918-23	7	46
132	Use of antithrombotic agents during pregnancy. <i>Chest</i> , <b>1992</b> , 102, 385S-390S	5.3	46

131	Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy. <i>American Journal of Clinical Pathology</i> , <b>1991</b> , 95, 222-7	1.9	45
130	Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. <i>Annals of Internal Medicine</i> , <b>2003</b> , 138, 720-3	8	44
129	Differences in inhibition of PGI <sub>2</sub> production by aspirin in rabbit artery and vein segments. <i>Thrombosis Research</i> , <b>1980</b> , 20, 447-60	8.2	44
128	Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. <i>Chest</i> , <b>1989</b> , 95, 88S-97S	5.3	43
127	The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. <i>Translational Research</i> , <b>1997</b> , 130, 649-55		42
126	Mechanism of action and monitoring of anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1986</b> , 12, 1-11	5.3	42
125	Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. <i>Circulation</i> , <b>1997</b> , 95, 118-24	16.7	42
124	The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. <i>Thrombosis Research</i> , <b>1980</b> , 20, 391-403	8.2	41
123	Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 409-17	8	40
122	New anticoagulants. <i>American Heart Journal</i> , <b>2001</b> , 142, S3-8	4.9	39
121	Venous thromboembolism after long flights: are airlines to blame?. <i>Lancet, The</i> , <b>2001</b> , 357, 1461-2	4.0	39
120	Prevention of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1976</b> , 2, 232-90	5.3	39
119	The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 68, 064-068	7	39
118	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 798-807	7	38
117	The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. <i>Chest</i> , <b>1998</b> , 114, 115S-118S	5.3	38
116	Antithrombotic agents in coronary artery disease. <i>Chest</i> , <b>1992</b> , 102, 456S-481S	5.3	38
115	Low Molecular Weight Heparin. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 204-207	7	38
114	Introduction: Antithrombotic Therapy—the Evolving Consensus. <i>Chest</i> , <b>1998</b> , 114, 439S-440S	5.3	37

113	Use of anticoagulants during pregnancy. <i>Chest</i> , <b>1989</b> , 95, 156S-160S	5.3	37
112	Deep Vein Thrombosis: New Non-Invasive Diagnostic Tests. <i>Thrombosis and Haemostasis</i> , <b>1991</b> , 66, 133-137		37
111	New antithrombotic agents--insights from clinical trials. <i>Nature Reviews Cardiology</i> , <b>2010</b> , 7, 498-509	14.8	36
110	AHA Scientific Statement: Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2001</b> , 21, E9-9	9.4	36
109	Rationale behind the development of low molecular weight heparin derivatives. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1985</b> , 11, 13-6	5.3	36
108	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. <i>British Journal of Haematology</i> , <b>2009</b> , 146, 142-9	4.5	34
107	Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. <i>Chest</i> , <b>1992</b> , 102, 364S-373S	5.3	34
106	New antithrombotics. <i>Chest</i> , <b>1995</b> , 108, 471S-485S	5.3	33
105	Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. <i>Annals of the New York Academy of Sciences</i> , <b>1989</b> , 556, 304-12	6.5	32
104	Optimal Therapeutic Range for Oral Anticoagulants. <i>Chest</i> , <b>1989</b> , 95, 5S-11S	5.3	32
103	Vasoflux, a new anticoagulant with a novel mechanism of action. <i>Circulation</i> , <b>1999</b> , 99, 682-9	16.7	31
102	Risk of haemorrhage associated with long term anticoagulant therapy. <i>Drugs</i> , <b>1985</b> , 30, 444-60	12.1	31
101	Peripheral Oxygen Saturation in Older Persons Wearing Nonmedical Face Masks in Community Settings. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 2323-2324	27.4	31
100	The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells. <i>Thrombosis Research</i> , <b>1999</b> , 96, 373-81	8.2	30
99	Optimal intensity and monitoring warfarin. <i>American Journal of Cardiology</i> , <b>1995</b> , 75, 39B-42B	3	30
98	Low-molecular-weight heparin for the treatment of venous thromboembolism. <i>American Heart Journal</i> , <b>1998</b> , 135, S336-42	4.9	28
97	A comparison of lyophilized artificially depleted plasmas and lyophilized plasmas from patients receiving warfarin in correcting for coagulometer effects on international normalized ratios. <i>American Journal of Clinical Pathology</i> , <b>1995</b> , 103, 366-71	1.9	28
96	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , <b>2014</b> , 124, 689-99	2.2	26

95	The Optimal Intensity of Oral Anticoagulant Therapy. <i>JAMA - Journal of the American Medical Association</i> , <b>1987</b> , 258, 2723	27.4	26
94	Direct thrombin inhibitors in cardiovascular disease. <i>Nature Reviews Cardiology</i> , <b>2012</b> , 9, 402-14	14.8	24
93	New antithrombotic agents. <i>Chest</i> , <b>1998</b> , 114, 715S-727S	5.3	24
92	Platelet-inhibiting drugs (see parts). <i>New England Journal of Medicine</i> , <b>1975</b> , 293, 1236-40	59.2	24
91	Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Global Use of Strategies To Open occluded arteries in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 37, 1001-7	15.1	23
90	Observations in anticoagulant and thrombolytic therapy in pulmonary embolism. <i>Progress in Cardiovascular Diseases</i> , <b>1975</b> , 17, 335-43	8.5	23
89	Diagnosis of venous thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1976</b> , 2, 203-31	5.3	23
88	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 40, 231-9	5.1	22
87	Electrical foot stimulation: a potential new method of deep venous thrombosis prophylaxis. <i>Vascular</i> , <b>2010</b> , 18, 20-7	1.3	22
86	Substandard Monitoring of Warfarin in North America. <i>Archives of Internal Medicine</i> , <b>1992</b> , 152, 257		22
85	Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. <i>American Heart Journal</i> , <b>1992</b> , 123, 1115-22	4.9	22
84	Effect of Streptokinase on Hemostasis. <i>Blood</i> , <b>1968</b> , 32, 726-737	2.2	22
83	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1049-57	7	21
82	Diagnosis and treatment of venous thromboembolism. <i>Annual Review of Medicine</i> , <b>2002</b> , 53, 15-33	17.4	21
81	Rationale for development of low-molecular-weight heparins and their clinical potential in the prevention of postoperative venous thrombosis. <i>American Journal of Surgery</i> , <b>1991</b> , 161, 512-8	2.7	21
80	Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. <i>Translational Research</i> , <b>1998</b> , 132, 181-5		20
79	Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 9755-61	5.4	20
78	Diagnosis of venous thrombosis and pulmonary embolism. <i>American Journal of Cardiology</i> , <b>1990</b> , 65, 45C-49C		20

77	Clinical use of low molecular weight heparins and heparinoids. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1988</b> , 14, 116-25	5.3	19
76	Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. <i>American Heart Journal</i> , <b>1998</b> , 136, 868-76	4.9	18
75	Aspirin and Other Platelet-Active Drugs. <i>Chest</i> , <b>1992</b> , 102, 327S-336S	5.3	18
74	Special report: a simple system for the derivation of International Normalized Ratios for the reporting of prothrombin time results with North American thromboplastin reagents. <i>American Journal of Clinical Pathology</i> , <b>1989</b> , 92, 124-6	1.9	18
73	Antithrombotic agents in coronary artery disease. <i>Chest</i> , <b>1986</b> , 89, 54S-67S	5.3	18
72	Duration of Anticoagulant Therapy After First Episode of Venous Thrombosis in Patients With Inherited Thrombophilia. <i>Archives of Internal Medicine</i> , <b>1997</b> , 157, 2174		17
71	Pulmonary Embolism in the Elderly. <i>Cardiology Clinics</i> , <b>1991</b> , 9, 457-474	2.5	17
70	Comparative value of tests for the diagnosis of venous thrombosis. <i>World Journal of Surgery</i> , <b>1978</b> , 2, 27-38	3.3	17
69	Diagnosis of pulmonary embolism. <i>Journal of the American College of Cardiology</i> , <b>1986</b> , 8, 128B-136B	15.1	16
68	Reduction in Mortality Following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 668-674	7	15
67	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , <b>2017</b> , 1, e139-e145	2.7	15
66	The emerging role of low-molecular-weight heparin in cardiovascular medicine. <i>Progress in Cardiovascular Diseases</i> , <b>2000</b> , 42, 235-46	8.5	15
65	Familial Thrombophilia: A Review Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>1996</b> , 2, 227-236	3.3	15
64	Treatment of venous thromboembolism. <i>Chest</i> , <b>1986</b> , 89, 426S-433S	5.3	15
63	Effectiveness of anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1986</b> , 12, 21-37	5.3	15
62	Ventilation-Perfusion Lung Scanning and the Diagnosis of Pulmonary Embolism: Improvement of Observer Agreement by the Use of a Lung Segment Reference Chart. <i>Thrombosis and Haemostasis</i> , <b>1992</b> , 68, 245-249	7	15
61	Treatment of Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>1999</b> , 82, 870-877	7	14
60	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , <b>2016</b> , 30, 25-9	7.4	13

59	Heparin resistance in acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2007</b> , 23, 93-100	10.1	13
58	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2012</b> , 144, 944-950.e3	1.5	12
57	Guidelines for anticoagulant use in acute coronary syndromes. <i>Lancet, The</i> , <b>2008</b> , 371, 1559-61	4.0	12
56	Dose antiplatelet agents; the relationship among side effects, and antithrombotic effectiveness. <i>Chest</i> , <b>1986</b> , 89, 4S-10S	5.3	12
55	Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. <i>Chest</i> , <b>2015</b> , 148, 587-595	5.3	11
54	Aspirin response variability after major orthopedic surgery. <i>Thrombosis Research</i> , <b>2012</b> , 130, 216-20	8.2	11
53	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1323-1329	7	11
52	The development and validation of an instrument to measure the quality of health research reports in the lay media. <i>BMC Public Health</i> , <b>2017</b> , 17, 343	4.1	10
51	Oral Anticoagulants. <i>Chest</i> , <b>1992</b> , 102, 312S-326S	5.3	10
50	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 70, 1-7	3.9	9
49	Antiplatelet drugs in thromboembolism. <i>Postgraduate Medicine</i> , <b>1979</b> , 66, 119-23, 126-7	3.7	9
48	125I-Labeled Fibrinogen Scanning. <i>JAMA - Journal of the American Medical Association</i> , <b>1975</b> , 233, 970	27.4	9
47	Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis. <i>Thrombosis and Haemostasis</i> , <b>1991</b> , 65, 541-544	7	9
46	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 10-3	7	8
45	Antithrombin-heparin covalent complex reduces microemboli during cardiopulmonary bypass in a pig model. <i>Blood</i> , <b>2010</b> , 116, 5716-23	2.2	8
44	Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis). <i>American Heart Journal</i> , <b>2001</b> , 142, 237-43	4.9	8
43	Prophylaxis of Venous Thromboembolism. <i>Chest</i> , <b>1986</b> , 89, 374S-383S	5.3	8
42	Clinical efficacy of heparin fractions: issues and answers. <i>CRC Critical Reviews in Clinical Laboratory Sciences</i> , <b>1986</b> , 23, 77-94		8

41	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1895-1901	7	8
40	Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation. <i>TH Open</i> , <b>2018</b> , 2, e190-e201	2.7	8
39	Anticoagulant therapy in venous thromboembolism. <i>Best Practice and Research: Clinical Haematology</i> , <b>1990</b> , 3, 685-92		7
38	Sample Size in the Planning and Interpretation of Clinical Trials. <i>Thrombosis and Haemostasis</i> , <b>1987</b> , 58, 953-956	7	7
37	Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance. <i>Thrombosis and Haemostasis</i> , <b>1990</b> , 64, 559-563	7	7
36	Comparative effects of heparin and LMW heparin on hemostasis. <i>Thrombosis Research</i> , <b>1991</b> , 14, 11-7	8.2	6
35	Optimal dosage regimens of tissue-type plasminogen activator. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1987</b> , 13, 160-2	5.3	6
34	Venous Thromboembolism: Diagnosis, Treatment, Prevention. <i>Hospital Practice (1995)</i> , <b>1975</b> , 10, 53-62	2.2	6
33	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , <b>1993</b> , 70, 443-447	7	6
32	Low-molecular-weight heparin for the out-of-hospital treatment of venous thrombosis: rationale and clinical results. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1997</b> , 23, 77-81	5.3	5
31	Use of plasminogen activators in venous thrombosis. <i>World Journal of Surgery</i> , <b>1990</b> , 14, 688-93	3.3	5
30	Increased platelet destruction. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1982</b> , 8, 75-82	5.3	5
29	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , <b>2018</b> , 101, 362-367	3.8	4
28	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2906-2907	15.1	4
27	Solving the mystery of excessive warfarin-induced bleeding: a personal historical perspective. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 853-6	7	3
26	Clinical potential of low molecular weight heparins. <i>Best Practice and Research: Clinical Haematology</i> , <b>1990</b> , 3, 545-54		3
25	Prophylaxis and therapy of venous thromboembolism. <i>CRC Critical Reviews in Clinical Laboratory Sciences</i> , <b>1979</b> , 10, 247-74		3
24	Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin. <i>Advances in Experimental Medicine and Biology</i> , <b>1992</b> , 313, 283-95	3.6	3

23	Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 46, 310-315	5.1	2
22	Deep Vein Thrombosis Prophylaxis: Response. <i>Chest</i> , <b>2009</b> , 136, 1700-1701	5.3	2
21	The Diagnosis of Clinically Suspected Pulmonary Embolism. <i>Chest</i> , <b>1986</b> , 89, 417S-425S	5.3	2
20	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study.. <i>TH Open</i> , <b>2022</b> , 6, e10-e17	2.7	2
19	Fixed-Dose, Weight-Adjusted, Unfractionated Heparin (UFH) Given Subcutaneously (sc) without Laboratory Monitoring for Acute Treatment of Venous Thromboembolism (VTE): Randomized Comparison with Low-Molecular-Weight-Heparin (LMWH).. <i>Blood</i> , <b>2004</b> , 104, 707-707	2.2	2
18	Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study. <i>Blood</i> , <b>2016</b> , 128, 2617-2617	2.2	2
17	Antithrombotic drugs for thromboembolic disorders: a lesson in evidence-based medicine. <i>American Journal of Health-System Pharmacy</i> , <b>1997</b> , 54, 1992-4	2.2	1
16	Low-molecular-weight heparin for anticoagulation during continuous venovenous hemofiltration. <i>Archives of Internal Medicine</i> , <b>2003</b> , 163, 981; author reply 981		1
15	Developing a novel antithrombotic in the academic environment. <i>Seminars in Hematology</i> , <b>2001</b> , 38, 4-114		1
14	New antithrombotics for the treatment of acute and chronic arterial ischemia. <i>Vascular Medicine</i> , <b>1996</b> , 1, 72-8	3.3	1
13	Clinical Utility of Impedance Plethysmography in the Diagnosis of Recurrent Deep-Vein Thrombosis. <i>Archives of Internal Medicine</i> , <b>1988</b> , 148, 519		1
12	Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. <i>Future Cardiology</i> , <b>2021</b> , 17, 175-182	1.3	1
11	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. <i>TH Open</i> , <b>2021</b> , 5, e84-e88	2.7	1
10	Antithrombotic Therapy <b>2012</b> , 171-177		
9	Is There a Relationship Between the Intensity of Heparin Treatment and Recurrent Thromboembolism?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>1997</b> , 3, S64-S67	3.3	
8	Low-Molecular-Weight Heparin Should Replace Unfractionated Heparin for Treatment of Venous Thrombosis and Unstable Angina. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1997</b> , 4, 349-351	5.1	
7	Oral Anticoagulant Therapy Recommendations. <i>Chest</i> , <b>1994</b> , 105, 328	5.3	
6	Aspirin and Other Platelet Active Drugs. <i>Chest</i> , <b>1989</b> , 95, 12S-18S	5.3	



- 5 In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1986**, 16, 82-6
- 4 Practical application of 125I-fibrinogen leg scanning. *CRC Critical Reviews in Clinical Laboratory Sciences*, **1981**, 14, 241-55
- 3 Significance: Clinical or Statistical?-Rebuttal. *Thrombosis and Haemostasis*, **1989**, 61, 325-325 7
- 2 Small dose subcutaneous heparin in preventing deep venous thrombosis **1975**, 233-242
- 1 Letter by de Vries et al Regarding Article "Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis".. *Circulation: Cardiovascular Quality and Outcomes*, **2022**, 101161CIRCOUTCOMES122008982 5.8